Abiraterone acetate is a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer. It significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone. The study, published Sept. 24 in iLancet Oncology/i, was led by Ethan Basch, MD, director of the Cancer Outcomes Research Program at the University of North Carolina Lineberger Comprehensive Cancer Center. Researchers ...Saturday, 28 September 2013
In Men With Metastatic Prostate Cancer Abiraterone Acetate Delays Quality of Life Decline: Study
Abiraterone acetate is a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer. It significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone. The study, published Sept. 24 in iLancet Oncology/i, was led by Ethan Basch, MD, director of the Cancer Outcomes Research Program at the University of North Carolina Lineberger Comprehensive Cancer Center. Researchers ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment